ISOROTIGOTINE PATCH FOR THE TREATMENT OF DYSKINESIAS 

VALUE PROPOSITION

·         Patch formulation: higher convenience for patients and better tolerability by more stable plasma levels

·         Combination of therapeutic (anti-dyskinetic) and disease modifying (neuroprotective) properties

·         Mode of action with clinical proof of concept for dyskinesias and neuroprotection, yet no marketed drug

MODE OF ACTION

Isorotigotine is a close chemical analogue to Rotigotine (Neupro®) with completely different pharmacological profile.

TARGET INDICATION RATIONALE

Dyskinesias are the most common side effect of Parkinson’s Disease therapies occurring in the majority of patients. Approaches to design novel drugs to avoid this particular side-effect were largely unsuccessful. An alternative is the add-on therapy with specific anti-dyskinetic drugs. Among the mechanisms discussed for the amelioration of levodopa induced dyskinesias 5-HT1A agonism is one of the most efficacious and best documented.

DEVELOPMENT STAGE

Preclinical Development, ca 1 year from IND

KEY DATA

Disease model: Blockade of L-DOPA induced dyskinesias in chronic rat model

Formulation feasibility assessment: Pilot patches available